FDA OKs AstraZeneca’s rare disease drug, but only for a subset of patients

Damian Garde

The FDA approved AstraZeneca's for a diabetes-related , but, following a vote from a panel of advisers,  for a portion of a tiny patient population, putting a clamp on already staid sales estimates.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS